Status:
UNKNOWN
Prospective Study on the Role of Intravenous Unfractionated Heparin Following Digital Replantation and Revascularization
Lead Sponsor:
Centre hospitalier de l'Université de Montréal (CHUM)
Conditions:
Amputation; Traumatic, Hand
Eligibility:
All Genders
14+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to determine the effectiveness of therapeutic dose intravenous heparin at improving replantation/revascularization success and its indications (if any) in participants who...
Eligibility Criteria
Inclusion
- All replantation and revascularization patients who are accepted into the CEVARMU program at the Centre hospitalier de l'Université de Montréal
Exclusion
- Patients on anticoagulants, other than ASA, prior to admission (i.e. Coumadin, Eliquis, Pradaxa, Plavix, or similar medications)
- Patients with a contraindication for heparin (e.g. coagulopathy, acute ulcers, thrombocytopenia, severe liver damage, shock)
- Patients who suffered an amputation in the level of the carpal tunnel and proximal to it
- Patients who experienced a degloving injury
Key Trial Info
Start Date :
May 24 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2025
Estimated Enrollment :
188 Patients enrolled
Trial Details
Trial ID
NCT04725201
Start Date
May 24 2021
End Date
May 1 2025
Last Update
July 27 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHUM
Montreal, Quebec, Canada, H2X 3E4